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Abstract Inter occasion variability (IOV) is of impor-
tance to consider in the development of a design where
individual pharmacokinetic or pharmacodynamic parame-
ters are of interest. IOV may adversely affect the precision
of maximum a posteriori (MAP) estimated individual
parameters, yet the influence of inclusion of IOV in opti-
mal design for estimation of individual parameters has not
been investigated. In this work two methods of including
IOV in the maximum a posteriori Fisher information
matrix (FIMMAP) are evaluated: (i) MAPocc—the IOV is
included as a fixed effect deviation per occasion and
individual, and (ii) POPocc—the IOV is included as an
occasion random effect. Sparse sampling schedules were
designed for two test models and compared to a scenario
where IOV is ignored, either by omitting known IOV
(Omit) or by mimicking a situation where unknown IOV
has inflated the IIV (Inflate). Accounting for IOV in the
FIMMAP markedly affected the designs compared to
ignoring IOV and, as evaluated by stochastic simulation
and estimation, resulted in superior precision in the indi-
vidual parameters. In addition MAPocc and POPocc accu-
rately predicted precision and shrinkage. For the
investigated designs, the MAPocc method was on average
slightly superior to POPocc and was less computationally
intensive.
Keywords Inter occasion variability (IOV)  Optimal
design (OD)  Maximum a posteriori (MAP)  Fisher
information  Bayesian  Pharmacometrics  Shrinkage
Introduction
Inter occasion variability (IOV) is increasingly quantified
in nonlinear mixed effect (NLME) models, but the impact
of this type of variability on the optimal experimental
design (OD) for the estimation of individual parameters is
not clear. The NLME approach splits the model in fixed
effects describing the typical population value parameters
and different levels of random effects. Typically in phar-
macokinetic (PK) and pharmacodynamic (PD) analyses
inter individual variability (IIV) and residual error (RE) are
estimated, but if variability between occasions (e.g.
between dosing occasions or observation periods) is
apparent IOV could be introduced as a third level of ran-
dom effects [1].
With a Bayesian approach individual and occasion
deviations from the typical population parameters can be
estimated given a population model, its population
parameter estimates, and individual observations. Individ-
ual parameter estimates, referred to as Empirical Bayes
Estimates (EBEs), can be derived by Maximum a Posteri-
ori (MAP) estimation and are of interest in e.g. model
diagnostics [2], covariate analysis [3, 4] and feedback dose
individualization [5]. Good precision of the EBEs are
therefore of importance for effective model evaluation and
for understanding and determination of individual differ-
ences in PK and PD. Characterization of individual
parameters can also be of importance for establishing
concentration-effect relationships [6]. If little information
is provided about the individual parameters the patient will
be regarded as a typical representative of the population
and the predicted EBEs will be close to the typical popu-
lation predictions, an effect known as g-shrinkage [2].
Conversely, if the individual information is rich the prior
population information will have smaller influence and the
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predicted EBEs will be closer to the ‘‘true’’ individual
values. The information richness of an individual may be
improved by increasing the quantity of samples or by
increasing the quality per sample, e.g. by optimal design
(OD) methodology [7].
In OD a design criterion is used to link the experimental
design to the measure of interest, commonly the joint
precision of the parameter estimates. The determinant of
the maximum a posteriori Fisher Information Matrix
(FIMMAP), first suggested for NLMEs by Merle´ and Mentre´
in 1995 under the name Bayesian Information Matrix [8],
may be used as optimization criterion for individual devi-
ation EBEs (henceforth called gEBE) [9, 10]. The FIMMAP
is the expectation of the individual FIM over the IIV dis-
tribution with the population distribution as prior infor-
mation. The FIMMAP follows the Crame´r-Rao inequality so
that its inverse is the lower bound for the expected poste-
rior covariance matrix of an unbiased estimator of the
individual parameters [8]. Hence the expected posterior
covariance matrix of the gEBEs may be minimized by
maximizing the inverse FIMMAP. Two additional metrics
has been proposed to more closely follow the true posterior
covariance matrix than the FIMMAP: the expected infor-
mation provided by the experiment, and the pre-posterior
covariance matrix (familiarly obtained through e.g.
stochastic simulation and estimation) [8]. While the
expected information provided by the experiment has been
employed for design optimization [11], these methods are
considerably more computationally demanding compared
to the FIMMAP [8, 12] and will not be further considered in
this work.
Even though IOV has long been recognized to be of
importance in NLME and neglecting IOV may negatively
affect the precision of MAP estimated gEBE [1], the
inclusion of IOV has not been previously investigated for
individual OD in a NLME framework. This work aims to
evaluate possible design criteria permitting OD for indi-
vidual parameter estimates in the presence of IOV. As a
driving example the design of a study (AIDA) aimed at
correlating individual PK of the antibiotic colistin with
patient covariates and treatment outcome is used (www.
aida-project.org). The trial will include over 300 patients
and a sparse sampling design was to be suggested. Colistin
was first used in the fifties but was later abandoned due to
toxicity concerns and hence sufficient exposure–response
information is missing. During recent years colistin has
seen resurgent use in treatment of multi drug resistant gram
negative infections [13]. A recent PK model for colistin
and its prodrug colistimethate sodium (CMS) by Mohamed
et al. [14] has quantified pronounced IOV in the PK
parameters and this model was considered for MAP esti-
mation of individual parameters from the AIDA study. The
OD of a sampling schedule was however hampered by the
current lack of methods to handle the IOV contributions in
the model. The model has a complex random effects
structure and a combined residual error model and the
colistin PK model will thus serve as a complex example of
MAP optimization in the presence of IOV. In addition to
the colistin PK model a simple constructed 1-compartment
IV-bolus population PK model with an additive or com-
bined (additive plus proportional) residual error model
(1-COMP) will be employed as a simpler test case.
Two possible methods to include IOV in the FIMMAP
were explored: (i) MAPocc where the IOV is included as an
individual deviation per occasion and individual, and (ii)
POPocc where the IOV is included as an occasion random
effect. These methods were compared against two cases
ignoring IOV, (i) Omit where the known IOV was omitted
from the FIMMAP, and (ii) Inflate mimicking a situation
where the study design neglected the possibility to quantify
IOV, e.g. by placing all samples in one occasion within an
individual. The methods were evaluated in terms of gEBE
precision (measured by simulation and MAP re-estimation)
and estimation run-times for discrete designs with fixed
sampling times (i.e. the same design for all individuals).
We also considered the correspondence between predicted
and evaluated precisions in gEBE as well as the ease of use
of the evaluated methods. Recently a method to predict
shrinkage in the distribution of gEBE from the FIMMAP was
presented by Combes et al. [15]. The ability of this method
to predict shrinkage from the FIMMAP with the proposed
additions was here evaluated as a secondary objective. To
accurately predict the precision and shrinkage of the gEBE
is of value as it would allow design appraisal without
secondary simulation based methods.
Methods
Model structure
The test models used in this work are NLME models where
the ith vector of individual responses yi is defined as:
yi ¼ f vi; g h; gi; j1;i; j2;i. . .; jm;i
  




where g() is the vector function describing the parameters
for the ith individual defined by the typical population
parameter vector h ¼ h1; h2; . . .hdf g, the individual devia-
tions vector gi ¼ g1; g2; . . .guf gN 0;Xð Þ; and the m occa-
sion deviation vectors jx;i ¼ j1; j2; . . .jvf gN 0;Pð Þ. f()
describe the structural model dependent on the individual
design given by vi and h() is the error model dependent on
the residual error deviation vector iN 0;Rð Þ. The
Matrices X, P, and R describe the covariances of the
individual, occasion and residual error deviations
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respectively. In this work all individuals were set to have
the same elementary design, i.e. vi ¼ v, although this is
not necessary within this framework.
Colistin PK
The PK model applied for colistin and its prodrug CMS
consists of one compartment for the formed colistin (Col)
and two compartments for CMS, i.e. the central (CMS1)
and peripheral (CMS2) compartments [14]. Parameter
values are presented in Table 1. The structural model is

































where Ax is the drug amount, CLx the clearance (CL/fm for
colistin) and Vx the volume of compartment x (V/fm for
colistin). The CL of colistin and CMS1 are 100 % corre-
lated and share the common IIV random effect gCL, with
hsc scaling the difference in the magnitude of IIV. Q is the
intercompartmental clearance between compartments
CMS1 and CMS2, and fm the fraction of CMS metabolized
to colistin. The initial condition for all compartments is
zero and the dosing compartment is ACMS1.
The combined additive and proportional residual error
model includes IIV on the residual error of CMS allowing
the residual error variance to differ between individuals.
The dependent variables are the log transformed central
compartment concentration of CMS (DVCMS1) and colistin
concentration (DVCol) given in Eqs. 5, 6:
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residual error variance was fixed to one and scaled by a
proportional part given by hERx,prop, and an additive part
given by hERx,add, with the inter-individual variability
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For the Inflate case the IIV was inflated to accommodate
the IOV in order to mimic a scenario where insufficient
information to separate IIV and IOV caused all IOV to end
up in the IIV (e.g. all samples taken in only one occasion).
For the Colistin PK model by Mohamed et al. [14] (im-
plemented in NONMEM 7 [16] with the ADVAN5 solver
and FOCEI method) this was accomplished by removing
the IOV random effects and fixing the typical population
parameters (including the residual error parameters). The
model was then rerun on the original dataset and only the
IIV variances were estimated forcing the IOV variance into
the IIV. The new IIV matrix was taken as X*. The IIV
parameters for the Inflate case are presented along with the
original parameters in Table 1. For simplicity and com-
parability with the 1-COMP model the residual error was
not allowed to inflate.
In the clinical study a dosing regimen of 9MU
(413 lmol) CMS as load (30-min infusion), followed by a
maintenance dose of 4.5MU (30-min infusion) every
twelfth h (q12) is planned to be administered. One occasion
was defined as one dose interval, similar as in the model
development [14].
1-COMP








where A is the drug amount, V is the volume of distribution
and CL is the drug clearance. An additive or additive and
proportional (combined) residual error model was used.
The parameter values are found in Table 2. A q6 dosing
regimen given as 1 unit IV bolus was implemented with
one occasion per dose interval (6 time units).
As the IIV and IOV are included on the same parameters
the IOV inflated IIV,X*, for case Inflatewas taken as the sum





2* is the rth diagonal element ofX*. The original values and
the values for scenario Inflate can be found in Table 2.
FIMMAP
The approximation of the FIMMAP and the notation used
was based on the work by Hennig et al. [10]. Here we give
a brief description of the procedure, for a detailed
description please see Merle and Mentre [8].
In order to calculate the FIMMAP the population model
was transformed to an individual model transferring the
population random effect parameters, g, to individual
parameters, hg, sampled from X. The process is described
in Eq. 8:
pi ¼ g h; gið Þ ! g hh; hgi
 
; hgi N 0;Xð Þ ð8Þ
where pi is the parameter vector for individual i dependent
on the population parameters hh, and the individual
parameters hgi.
The FIMMAP is formed as the expectation of the indi-
vidual FIM for the transformed model over its prior, X1.
The expectation was here approximated by Monte Carlo
integration over all possible individual parameter values.
The procedure is given by:












with n being the number of individual parameter sets
sampled.
Inclusion of IOV in the FIMMAP
MAPocc
The IOV was added to the individual FIM as an occasion
deviation sampled per individual occasion from the prior
IOV distribution P. The prior IOV covariance matrix P
was utilized as occasion prior (Eq. 10).
Table 2 Parameter values for
the constructed 1-COMP model
Parameter Typical value IIV (%) IOV (%)
CV % X CV % P
CL 9 25 (35) 0.0625 (0.125) 25 (0) 0.0625 (0)
V 40 25 (35) 0.0625 (0.125) 25 (0) 0.0625 (0)
Additive residual error variance 1
Proportional residual error variance 0.04
Values in parenthesis are the IIV random effects inflated to include IOV. The variance parameters are
presented both as coefficient of variation (CV %—left) of the typical value and as variances (X or P—
right)
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FIMi;MAPocc ¼ FIM v; hh; hgi; hj1;i; hj2;i; . . .hjm;i
  
PriorMAPocc ¼ diag X1;P11 ;P12 ; . . .P1m
 
ð10Þ
where hjji is the vector of occasion deviations for the jth
occasion of the ith individual, m is the number of occasions
and Pj == P.
The inclusion of the occasion deviations in the MAPocc
approach is analogous to how the individual deviations are
handled in the FIMMAP (Eq. 8).
POPocc
The IOV was included in the individual FIM as an occasion
variance term:




PriorPOPocc ¼ diag X1; 0v;v
  ð11Þ
where 0v,v is the v-by-v zero matrix acting as prior for G,
and v is the number of occasion effects in the prior popu-
lation model. Using the first order (FO) approximation
proposed by Retout and Mentre´ [17] the occasion variance













fi :ð Þ ¼ f vi; g h; hgi; j1;i; j2;i. . .; jm;i
  
ð12Þ
As reference the designs were optimized without
inclusion of IOV (using the FIMMAP as is), either ignoring
the known IOV (case Omit) or using a prior IIV distribution
inflated with IOV (case Inflate). The latter mimic the model
result from a study design neglecting the possibility to
separate IIV and IOV.
Design optimization
The models were implemented in the ODs software PopED
version 2.13 [18] written in MATLAB (MATLAB
v.7.12.0.635) using the FO approximation of the FIM. The
prior FIM functionality was utilized to supply the prior IIV
covariance matrix X. PopED supports IOV as a population
random effect making the implementation of method
POPocc straightforward. The individual deviations vector
hgi for the FIM calculation was drawn from X and reused
for each model and optimization iteration to decrease the
Monte Carlo error. The occasion parameter vectors for the
MAPocc method hjj;i were sampled in the same manner.
The expectation of the logarithm of the determinant of the
interesting part of the FIM over the prior was employed as
the criterion to be maximized (Ds optimality [7]):





where FIMi,uninteresting is the FIM for uninteresting
parameters (defined below). For the MAPocc criterion the
occasion deviation parameters hjj;i were taken as uninter-
esting while the POPocc method was computed with the
occasion variance parameters P fixed. In all cases (Omit,
Inflate, MAPocc, POPocc) the residual error variances, R,
and the population parameters, hh, were fixed.
The sampling schedules for the two test models were
optimized using the PopED Random Search, Stochastic
Gradient and Line search methods as described by Nyberg
et al. [18]. Schedules of 3 or 6 sampling times over 36 h
(three occasions) were investigated for the colistin PK
model. The number of samples was selected as the smallest
number needed to identify the g deviations in the absence
of IOV and adding one extra sample per investigated
occasion (3 and 3 ? 3). Sampling was prohibited during
and up to 15 min post infusion by setting the information to
zero for samples placed in these intervals. Both CMS and
colistin concentrations were assumed to be analysed at
each time point. For the 1-COMP model a sampling
schedule of 5 samples was optimized over 24 h, with no
restriction in time. In order to investigate sampling clus-
tering behaviour the number of samples were set to exceed
the number needed to identify the g deviations in the
absence of IOV.
Standard error prediction
The predicted individual standard error (iSE) of the indi-
vidual parameters (hgi) were computed as the square root of
the diagonal of the inverse individual FIM plus the prior:
iSEpred ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
diag FIMi þ Priorð Þ1
q
ð14Þ
where iSEpred is the 1-by-u vector of predicted mean
standard deviations of the u model gEBEs of individual i.
Shrinkage prediction
Combes et al. [15] calculated the expected shrinkage (SH)
in the gEBEs from the FIMMAP and its prior according to:
SHpred;VAR ¼ diag FIM1MAP  Prior
  ð15Þ
where SHpred,VAR is the 1-by-u vector of predicted
shrinkages of the u model gEBEs on a variance scale.
Equation 15 quantifies the information gain of the
FIMMAP compared to its prior; if no information is gained
the FIMMAP will be equal to its prior and the SH will be 1,
conversely if much information is gained the FIMMAP is
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large compared to its prior and the SH is low. The accuracy
of the prediction is however dependent on how well the
FIMMAP reflect the individual information loss in the gEBE.
The FIMMAP may be substituted for the expected covari-
ance matrix, i.e. the expectation of the inverse of the
individual FIM plus its prior, which directly account for the
individual contribution to the total SH as the inverse of the
FIM is performed prior to summation. The predicted SH is
then written:









The expression in Eq. 16 is corresponding to the
expected shrinkage over the n sampled individual param-
eter sets. Commonly in pharmacometrics (e.g. [2])
shrinkage is presented on the standard deviation scale,













where SHpred is the vector of predicted shrinkages of the
u model gEBEs on a standard deviation scale.
Computation time
The computation time for each method was assessed as the
mean estimation time of 100 individual FIM calculations
on an Intel i7 2.7 GHz machine running MATLAB
v.7.12.0.635 on Windows 7.
Design evaluation
The performance of the designs was assessed via 10,000
Monte Carlo simulation–MAP estimation procedures of the
designs using the full population model implemented in
NONMEM 7.3 (Colistin PK: ADVAN5, FOCEI, 1-Com-
partment IV-bolus: ADVAN1, FOCEI). The simulation/
estimation was carried out using the SSE functionality in
PsN v.4.0.1 [19] with gEBEs estimated by setting the
MAXEVAL = 0 and MCETA = 1000 option in NON-
MEM. The individual SEs (iSEexp) of the EBEs were
obtained as the square root of the individual predicted gEBE
variance from the NONMEM 7.phi file, see Kang et al. [20].
The coefficient of determination (R2) between the sim-
ulated g and the MAP estimated gEBE was used as a










2 is the R2 of the rth gEBE, gi,r is the rth simulated
individual deviation for individual i, gr is the mean of the
rth simulated individual deviation (in the ideal case equal
to 0), gEBEi;r is the corresponding EBE, and n is the number
of simulated individuals (here 10,000). Note that negative
R2 values are possible if the variance of the difference
between the simulated and the estimated deviations is
larger than the variance of the simulated values, i.e. the
precision of the re-estimation is worse than what would be
achieved if each value was set to the mean.






where SHr is the shrinkage of the rth gEBE on standard
deviation scale and xr is the prior standard deviation.
Results
Designs
The two cases ignoring the IOV in the optimization (Omit
and Inflate) resulted in identical 5-sample designs for the
1-COMP additive error model (Fig. 1, top panel) placing
duplicate samples at Cmax in the first occasion (first dosing
interval) and three samples in the last occasion, a single
sample at Cmax and a duplicate sample in the middle. The
MAPocc method allocated single samples across all occa-
sions (two samples in the last occasion) while POPocc
sampled the first, third and last occasion. When the pro-
portional residual error was added the Omit and Inflate
cases again resulted in identical designs with duplicate
sampling of the Cmax of the first occasion and triplicate
sampling of the Cmin of the last occasion. MAPocc and
POPocc placed samples early and/or late in each occasion
(Fig. 1, 2nd panel).
For the Colistin PK model the Omit and Inflate methods
also resulted in identical designs placing a single sample at
the first available time of the first occasion and duplicate
samples at the end of the last occasion for the three sample
design (Fig. 1, 3rd panel). For the six-sample design trip-
licate samples were included in the first occasion plus three
clustered samples at the end of the last occasion (Fig. 1,
bottom panel). In contrast the MAPocc and POPocc methods
placed single samples at the start, middle and end of the
first occasion for the three sample design. For the six
sample design the MAPocc method added duplicate samples
740 J Pharmacokinet Pharmacodyn (2015) 42:735–750
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at the start and end of the first occasion and a single sample
at the end of the second occasion while the POPocc added
duplicate samples to the start and middle of the first
occasion and a single sample at the end of the last occasion.
The general layout of the designs produced by each
method was robust to the random seed used to initiate the
optimization. E.g. for the 3 sample Colistin PK design an
alternate deviation vector shifted the sampling times by
*1 % of the dosing interval.
Re-estimation
As the Omit and Inflate cases provided identical designs
the re-estimation performance will only be presented for
the Omit design.
For the 1-COMP additive residual error model the
baseline Omit design performed the worst for both
parameters (gCL: R
2 = 0.52 and SH = 28 %, gV:
R2 = 0.64 and SH = 21 %) and MAPocc performed the
Fig. 1 PK profiles of models
1-COMP (top) and Colistin PK
(middle and bottom, Colistin
solid line, CMS dashed line)
and sampling schedules for the
Omit, Inflate, MAPocc, and
POPocc (from top to bottom in
each panel) with the number of
samples per time point indicated
on horizontal lines. For all
models samples are assumed to
be taken post-dose in the
respective occasion
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best (gCL: R
2 = 0.66 and SH = 19 %, gV: R
2 = 0.73 and
SH = 14 %) (Fig. 2). POPocc had intermediate perfor-
mance (gCL: R
2 = 0.66 and SH = 20 %, gV: R
2 = 0.64
and SH = 20 %). Similar results were found for the
combined residual error model where the Omit design also
was the worst (gCL: R
2 = 0.43 and SH = 38 %, gV:
R2 = 0.09 and SH = 73 %) while MAPocc (gCL:
R2 = 0.63 and SH = 26 %, gV: R
2 = 0.54 and
SH = 26 %) and POPocc (gCL: R
2 = 0.59 and
SH = 24 %, gV: R
2 = 0.60 and SH = 23 %) had the best
performance for gCL and gV respectively (Fig. 3).
For the Colistin PK model 3 sample designs the gCL was
re-estimated with similar accuracy and precision
(R2 C 0.72) for all methods (Fig. 4, upper panel), while the
SH was lower for MAPocc and POPocc methods
(SH B 10 %) compared to Omit (SH = 13 %). MAPocc
achieved the highest precision (R2 = 0.74) and the lowest
SH (10 %). As the number of available samples was
increased to six the precision was unchanged for Omit
while the SH remained similar (R2 = 0.72, SH = 14 %)
(Fig. 5, upper panel). In contrast, for the MAPocc and
POPocc methods the precision increased and SH decreased
when the number of samples was doubled (R2 C 0.82,
SH B 8 %). POPocc performed the best (R
2 = 0.8,
SH = 8 %).
The gQ parameter was less well re-estimated (Figs. 4, 5
middle panels) compared to the gCl parameter and the
difference between the re-estimation performance of Omit
(3 samples: R2 = 0.04, SH = 70 %, 6 samples: R2 = 0.04,
SH = 67 %) and the MAPocc and POPocc methods (3
Fig. 2 Re-estimation
performance per design for the
1-COMP model with additive
error. gCL (top panel) and gV
(bottom panel), the coefficient
of determination with respect to
the simulated g (R2) and the g-
shrinkage (SH %) of the re-
estimation are given. Upper row
Simulated g versus
corresponding gEBE with the
line of identity (solid) and a
smooth of the intercepts
(dashed). Lower row
Distribution of simulated g
(solid line) and corresponding
gEBE (dashed line)
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samples: R2 C 0.17, SH B 27 %, 6 samples: R2 C 0.37,
SH B 23 %) was higher. Overall, the MAPocc designs had
the best performance (3 samples: R2 = 0.21, SH = 26 %,
6 samples: R2 = 0.38, SH = 23 %).
None of the 3-sample designs for the Colistin PK model
were able to re-estimate the gER parameter with R
2 values
above 0, and although SH was not high (\29 % for all
designs) the distributions were highly skewed (Fig. 4,
bottom panel). When the number of available samples was
increased to 6 the Omit design performed best in terms of
R2 (0.38) whereas MAPocc was best in terms of SH (0 %),
however all designs provided very low SH (\9 %) (Fig. 5,
bottom panel).
Correspondence between PopED and NONMEM
iSE
The correspondence between the individual SE (iSE) for
the g-parameters as given by the PopED prediction and
NONMEM evaluation are illustrated in Fig. 6. The agree-
ment between the iSE was evaluated both in terms of size
as given by the median, and in terms of spread in the
population as given by the inter quartile range (IQR).
For the 1-COMP model the correspondence of the
median iSE was poor for the Omit and Inflate scenarios and
best for the MAPocc method while the POPocc method had
slightly larger differences in the median iSE. The IQR was
Fig. 3 Re-estimation
performance per design for the
1-COMP model with combined
error. gCL (top panel) and gV
(bottom panel), the coefficient
of determination with respect to
the simulated g (R2) and the
g-shrinkage (SH %) of the
re-estimation are given. Upper
row Simulated g versus
corresponding gEBE with the
line of identity (solid) and a
smooth of the intercepts
(dashed). Lower row
Distribution of simulated g
(solid line) and corresponding
gEBE (dashed line)
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Fig. 4 Re-estimation
performance per design for the
Colistin PK 3-sample model
gCL (top panel), gQ (middle
panel) and gER (bottom panel),
the coefficient of determination
with respect to the simulated g
(R2) and the g-shrinkage
(SH %) of the re-estimation are
given. Upper row Simulated g
versus corresponding gEBE with
the line of identity (solid) and a
smooth of the intercepts
(dashed). Lower row
Distribution of simulated g
(solid line) and corresponding
gEBE (dashed line)
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Fig. 5 Re-estimation
performance per design for the
Colistin PK 6-sample model
gCL (top panel), gQ (middle
panel) and gER (bottom panel),
the coefficient of determination
with respect to the simulated g
(R2) and the g-shrinkage
(SH %) of the re-estimation are
given. Upper row Simulated g
versus corresponding gEBE with
the line of identity (solid) and a
smooth of the intercepts
(dashed). Lower row
Distribution of simulated g
(solid line) and corresponding
gEBE (dashed line)
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small for all designs with a slight tendency of overpre-
diction observed for Inflate, Omit, and MAPocc for both the
gCL and gV.
For the Colistin PK 3 and 6 sample designs, the Omit
and Inflate scenarios underpredicted both the iSE median
and IQR for the gCL and gQ parameters. For gER Omit
accurately predicted the observed median and the (very
small) IQR while Inflate overpredicted the median but
predicted the IQR well. MAPocc predicted the median and
IQR of the iSE well for all parameters. For the 3 sample
designs POPocc accurately predicted the median and IQR of
gCL and gQ while for the 6 sample design they accurately
predicted the gQ iSE and IQR. For both the 3 and 6 sample
designs POPocc overpredicted the gERE iSE median and
IQR.
Correspondence between predicted and observed
shrinkage
The cases Omit and Inflate strongly underpredicted the
observed SH for all models and parameters except for the
Colistin PK gER for which Omit moderately
underpredicted for the 3 sample design and overpredicted
for the 6 sample design (Fig. 7). For the 1-COMP model
the MAPocc and POPocc methods tended to moderately
underpredict the SH for both parameters. For the Colistin
PK model 3 sample design MAPocc accurately predicted
the SH in the gCl and gQ distributions and slightly
underpredicted the gER SH, while POPocc accurately pre-
dicted the SH of all three parameters. As the information
increased with the addition of three samples in the 6 sample
design the MAPocc and POPocc methods underpredicted the
gCL SH (MAPocc performing best, POPocc slightly worse),
accurately predicted the gQ SH and underpredicted the gER
SH.
Runtimes
Relative to the base FIMmap runtime (Omit and Inflate) the
runtime for one PopED FIM calculation for methods
MAPocc and POPocc of the 3-sample colistin PK design
were 1.8 and 38 times longer, respectively, and for the
1-COMP additive residual error model 4.0 and 46 times
longer, respectively (Fig. 8).
Fig. 6 Boxplots (1st, 2nd, 3rd
quartile ? whiskers) of the
distribution of individual SE
(iSE) per parameter and design
from PopED (SE of hik) and
NONMEM (SE of gEBE). The
upper whisker extend to the
highest value that is within 1.5 *
IQR of the 3rd quartile, where
IQR is the inter quartile range.
The lower whisker extends to
the lowest value within 1.5 *
IQR of the 1st quartile
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Discussion
The ability to optimize for individual parameter precision
in the presence of IOV could be important to improve the
ability to design studies reliant on precise individual
parameter estimates, e.g. feedback dose individualization.
However also studies with the aim of describing population
characteristics could be facilitated as many covariate model
building techniques utilize EBEs [3] and are thus inher-
ently reliant on precise individual parameter estimates [21].
The level of IOV limits the applicability for feedback dose
individualization [22] and is therefore important to con-
sider, but will also affect the precision with which indi-
vidual deviations may be estimated. OD with the aim of
providing precise individual parameter estimates for mod-
els including IOV has been investigated previously by e.g.
Nguyen et al. [23] where a standard population D-opti-
mality method was used. However this is to the authors’
knowledge the first effort to include handling of IOV in
individual OD using MAP based FIM.
The two cases of ignoring IOV in OD for individual
parameters resulted in identical designs. In contrast,
including the IOV as a fixed effect per occasion (MAPocc)
or as an occasion random effect (POPocc) markedly shifted
the design. The result that Inflate did not shift the design
relative to Omit may be anticipated as it does not convey
any information penalty for designs that cannot discrimi-
nate between individual and occasion deviations. In con-
trast, MAPocc and POPocc both treat the occasion deviations
as modeled variables. Hence lack of information to dis-
criminate between the individual and occasion deviations
directly impacts the expected parameter precision.
For the 1-COMP model with an additive residual error
this resulted in designs with a wide spread of samples over
the available occasions for methods MAPocc and POPocc,
maximizing the ability to discriminate between individual
Fig. 7 The predicted SH
(PopED) per parameter and
design (using the respective
methods) compared with the re-
estimated SH (NONMEM)
(using the full model)
Fig. 8 Runtime on a 2.7 GHz
intel i7 machine for one FIM
calculation for the two models
respectively
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and occasion deviations. In contrast Omit produced clus-
tered samples at the first and last occasion. When the pro-
portional residual error was introduced the emphasis was
shifted for all methods from sampling at high to low con-
centrations in an effort to minimize the noise. The general
sampling strategy was however similar to the additive
residual error case with Omit concentrating samples to two
time points while MAPocc and POPocc spread single samples
across all available occasions. When the impact of these two
strategies was evaluated it was apparent that the MAPocc and
POPocc designs provided higher accuracy and less shrinkage
and bias in the gEBE estimates compared with Omit,
regardless of the residual error model. In general the per-
formance of MAPocc was slightly superior to POPocc.
For the Colistin PK model the POPocc and MAPocc
3-sample designs concentrated all samples to the first
occasion while Omit also in this case sampled the first and
last occasion. The concentration of samples to one occasion
for MAPocc and POPocc is contrary to the 1-COMP design
(irrespectively of the residual error model) and the expec-
tation that maximizing the number of sampled occasions
would maximize the possibility of separating occasion and
individual deviations. The reason is the structure of the
random effects in the Colistin PK model as the occasion
and individual deviations are linearly independent with
respect to the model response. This make it possible to
separate the occasion and individual deviations on any one
occasion (Eqs. 2, 3, 4). It would thus be of advantage to
sample few and early occasions, as samples taken at late
occasions would be influenced by deviations from early
occasions carried forward in the PK profile. Additionally
for colistin there is a larger range of concentrations in the
first occasion providing information on the volume of
distribution. Three samples was sufficient to saturate the
first occasion for both MAPocc and POPocc and the addi-
tional three samples of the 6-sample design resulted in the
addition of one new sampling point at a later occasion as
well as duplicated samples. In contrast, for the Omit design
the added samples simply resulted in additional clustered
samples as the support points for the model without IOV
were already occupied.
For the Colistin PK model the re-estimation performance
of the MAPocc and POPocc designs was superior to the Omit
design except for the gER parameter (Figs. 4, 5) for which
the MAPocc and POPocc designs resulted in biased gEBE
distributions. The systematic negative bias of the re-esti-
mated gER may be due to an inability to sufficiently separate
the residual error and the occasion deviations leading to an
underestimation of the residual error variance. In contrast
the multiplicity of the sampling points in the Omit design
allowed more precise residual error characterization and
hence a better ability to determine the gER.
The effect of sampling in a limited number of occasions
for the two models was investigated by placing rich sam-
pling ([1 sample/h) in either the first occasion or in all
available occasions for the Colistin PK model and in either
the first, first and second, or all occasions for the 1-COMP
model. These designs were evaluated by simulation and
MAP reestimation in NONMEM (results not shown). For
the Colistin PK model rich sampling in one occasion was
sufficient to estimate all gEBEs with adequate precision and
shrinkage (R2 C 0.77, SH B 15 %) which was moderately
improved by rich sampling in all three occasions
(R2 C 0.88, SH B 11 %). As reflected in the 3 and 6
sample designs for methods POPocc and MAPocc, this result
confirms that due to linear independence of the random
effect parameters most information is available in the first
occasion for the Colistin PK model but that additional
information may be gained by adding samples in later
occasions. For the 1-COMP model there was a clear gain in
precision and decrease in shrinkage as the number of
sampled occasions was increased from the first (R2 C 0.48,
SH B 31 %), to the first and second (R2 C 0.63,
SH B 21 %), and finally to all four occasions (R2 C 0.74,
SH B 14 %). Again this result confirms the sampling
strategy of methods POPocc and MAPocc. In addition, for a
model where IIV and IOV variances are added to the same
fixed effect parameter, the result illustrates that the EBEs
will always be subject to shrinkage when a finite number
occasions are sampled. The iSE prediction was generally
good both in terms of size and spread for the MAPocc and
POPocc methods, albeit with a tendency of negative bias
(Fig. 6). In contrast methods Omit and Inflate behaved
poorly, however only Omit and MAPocc accurately pre-
dicted the Colistin PK gER iSE. A reason for the negative
bias of the predicted iSE may be that the prediction is
based on the symmetrical and centered X distribution
while the re-estimated iSE is based on the actual gEBE
from NONMEM. In an effort to increase the quality of the
NONMEM gEBE the MCETA option available in version
7.3 was used by which additional initial estimates for the
EBEs are tested.
The SH prediction by the MAPocc and POPocc methods
for the 1-COMP model was in the range of accuracy
demonstrated by Combes et al. [15] and excellent for
Colistin PK 3 sample design where the MAPocc method
predicted the gER SH with high accuracy. For the 6 sample
design the predictions deteriorated, possibly due to a larger
discrepancy between the observed and predicted g-vari-
ances. The Omit and Inflate methods failed to predict the
SH for all models and parameters except the Colistin PK
gER, the same trend may be noted for the iSE. The finding
that the SH prediction was worse for the simpler 1-COMP
model may be due to that the individual and occasion
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deviations in this model are added to the same parameter,
making the separation of these variances harder.
As expected, ignoring the IOV was fastest in terms of
computational effort followed by MAPocc by an increase
roughly proportional to the number of added parameters.
The POPocc method was associated with a pronounced
increase in computational effort due to the need to linearize
around the occasion random effects in addition to the
residual error [18]. The differences in computational effort
are not expected to be sensitive to the structure of the IIV
variances or the residual error model since these are the
same for the different methods. However the number of
occasions may potentially shift the computational effort of
POPocc and MAPocc as the latter needs one new set of
parameters added per occasion whereas POPocc instead has
to linearize over the additional occasions.
The clustering of samples (as observed for several of the
designs presented in this work) is a common behavior in
design optimization when the design is saturated, i.e. that
the support points needed to identify the model parameters
are populated, and any additional samples will be focused
on improving the signal-to-noise of the measurement [24].
The gain in parameter precision is however dependent on
the assumption that the errors of duplicate samples taken at
the same time are uncorrelated, an assumption that is
unlikely to hold for real data. The clustering behavior can
be avoided by acknowledging the inter dependence of
samples in the model building and design optimization
[24], or by empirically spreading the sampling clusters.
In this work it was only considered to add the occasion
variances as fixed parameters to the POPocc method as this
reflect the same assumption as for the MAPocc method;
namely that the variances of the occasion deviations are
known from the prior. The POPocc method could be further
expanded to consider the occasion random effect as unfixed
(set as interesting or uninteresting) in the optimization.
These alternative implementations were evaluated but
differences were found to be small compared with the
differences between the tested methods, both in the pro-
duced design and the predictability of the method (result
not shown). Additionally only FO based FIMs were eval-
uated, linearization of the model around the conditional
estimates of the occasion deviations (FOCE) may have
improved the performance of the POPocc method but would
have severely increased the run times. While the influence
of the balance between IIV, IOV, and residual error vari-
ances on the ability to precisely estimate gEBEs have not
been investigated here it is likely that higher degrees of
within subject variability (IOV and residual error) would
limit the precision of which the individual deviation
parameters may be estimated. However, in such a situation
the gEBEs are expected to be of less value for feedback
dose individualization or model diagnostics. We believe
the results are generalizable in the sense that large IOV
needs to be considered in the design of studies aiming to
estimate gEBEs. The exact sampling patterns are however
expected to be sensitive to differences in model structure
and random effect levels.
Conclusions
Two methods were formulated and applied to account for
IOV in the optimization for maximum precision in indi-
vidual parameters and evaluated against two scenarios of
ignoring the IOV. Directly accounting for IOV resulted in
designs markedly different from those suggested when
ignoring the IOV, with large gains in the precision of the
estimated individual deviation. In addition both methods
(MAPocc and POPocc) predicted the observed iSE and SH
well. In contrast, ignoring IOV, either by omitting known
IOV or by failing to separate IIV and IOV, led to overly
optimistic shrinkage and precision predictions, and lower
precision in the estimated individual parameters. While
differences between MAPocc and POPocc were slight, both
in the produced design and terms of predictability, MAPocc
was computationally much faster in the studied cases.
MAPocc is also attractive compared to POPocc as the
occasion deviations are handled analogously to the indi-
vidual deviations in the FIMMAP. The POPocc method is
however easier to implement in PopED and could be
advantageous if the number of occasions is large or if it is
suitable to consider the IOV distribution of interest to
estimate. Based on this work the authors would generally
recommend the use of method MAPocc in OD for indi-
vidual parameter estimates in the presence of IOV.
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